Proposed Issue of Securities — Appendix 3B
Imagion Biosystems has announced a Proposed Issue of Securities. Read the announcement.
IBX Raises $6M in Placement
Highlights: $6M raised in a heavily oversubscribed placement at 8.5c per share – a 6% discount to the 30-day VWAP. Placement strongly supported by…
Trading Halt
The securities of Imagion Biosystems will be placed in trading halt the request of IBX, pending it releasing an announcement. Read the ASX announcement and the…
Statement Pursuant to Listing Rule 4.7C.3
Imagion Biosystems advises that in accordance with Listing Rule 4.7C.3, and as noted in the Item 6 of the Appendix 4C Cashflow Statement lodged by the Company…
New Imaging Technology for Early Detection
Early detection is critical to improving cancer survival rates. Too often, the limitations of today's medical imaging technologies result in cancer being…
Appendix C and Quarterly Activity Report
Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on company activities for the quarter ending 30 September 2020 (Q3…
Quarterly Activity Report and Appendix C
Imagion Biosystems has released their Quarterly Activity Report for the period ended 30 September 2020 and Appendix C. Q3 Highlights Raised $4.7M (after…
Appendix 3Y — Change of Director's Interest Notice
Imagion Biosystems gave ASX information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Read…
Appendix 2A — Fully Paid Ordinary Shares
Imagion Biosystems has submitted "Appendix 2A — Application for quotation of +securities." Read Appendix 2A.
Vesting of Performance Rights
Imagion Biosystems has advised that 2,500,000 performance rights have vested and were issued as ordinary shares to Executive Chairman and CEO Bob Proulx today,…